Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OMER NASDAQ:RTRX NASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOMEROmeros$9.28$11.52$3.00▼$17.65$671.64M2.552.27 million shs1.38 million shsRTRXTravere Therapeutics$31.68+0.0%$26.56$8.98▼$24.96$1.62B0.67412,277 shs1.20 million shsTXMDTherapeuticsMD$2.11$2.06$0.99▼$2.95$24.42M0.5957,528 shs13,601 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOMEROmeros0.00%+7.04%-9.46%-14.86%+200.32%RTRXTravere Therapeutics0.00%0.00%0.00%+4.07%+115.36%TXMDTherapeuticsMD0.00%0.00%+5.50%+5.50%+85.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOMEROmeros$9.28$11.52$3.00▼$17.65$671.64M2.552.27 million shs1.38 million shsRTRXTravere Therapeutics$31.68+0.0%$26.56$8.98▼$24.96$1.62B0.67412,277 shs1.20 million shsTXMDTherapeuticsMD$2.11$2.06$0.99▼$2.95$24.42M0.5957,528 shs13,601 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOMEROmeros0.00%+7.04%-9.46%-14.86%+200.32%RTRXTravere Therapeutics0.00%0.00%0.00%+4.07%+115.36%TXMDTherapeuticsMD0.00%0.00%+5.50%+5.50%+85.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOMEROmeros 2.83Moderate Buy$38.00309.48% UpsideRTRXTravere Therapeutics 0.00N/AN/AN/ATXMDTherapeuticsMD 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest OMER, TXMD, and RTRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $33.006/10/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/2/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/14/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Hold (C-)5/14/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.004/21/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OMEROmeros D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.004/6/2026TXMDTherapeuticsMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOMEROmerosN/AN/A$1.87 per share4.96($1.71) per shareN/ARTRXTravere Therapeutics$175.34M9.22N/AN/A$5.15 per share6.15TXMDTherapeuticsMD$3.02M8.08$0.05 per share45.23$2.32 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOMEROmeros-$3.35M$0.7013.26132.57N/AN/A-102.16%64.87%8/13/2026 (Estimated)RTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/ATXMDTherapeuticsMD-$570K$0.0635.17N/AN/A5.34%0.32%0.23%8/17/2026 (Estimated)Latest OMER, TXMD, and RTRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026OMEROmeros-$0.40-$0.24+$0.16$0.62$4.19 million$9.89 million5/12/2026Q1 2026TXMDTherapeuticsMD-$6.1250$0.01+$6.1350$0.01$19.77 million$0.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthOMEROmerosN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOMEROmerosN/A3.033.03RTRXTravere Therapeutics0.667.237.14TXMDTherapeuticsMDN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOMEROmeros48.79%RTRXTravere TherapeuticsN/ATXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipOMEROmeros10.50%RTRXTravere Therapeutics4.63%TXMDTherapeuticsMD1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOMEROmeros21072.38 million64.78 millionOptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableTXMDTherapeuticsMD42011.57 million11.38 millionOptionableOMER, TXMD, and RTRX HeadlinesRecent News About These CompaniesTherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gainsJune 5, 2026 | marketwatch.comTherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comTherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comTherapeuticsMD Inc. stock outperforms competitors on strong trading dayApril 6, 2026 | marketwatch.comTherapeuticsMD Narrows 2025 Loss, Advances Royalty StrategyApril 2, 2026 | theglobeandmail.comTherapeuticsMD Explains Brief Delay In Annual FilingApril 1, 2026 | tipranks.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | finance.yahoo.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | businesswire.comTherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 SharesDecember 30, 2025 | insidertrades.comTherapeuticsMD approves key proposals at annual meetingDecember 16, 2025 | msn.comTherapeuticsMD: Q3 Earnings SnapshotNovember 13, 2025 | timesunion.comTTherapeuticsMD Reports Q3 2025 Financial ResultsNovember 13, 2025 | msn.comTherapeuticsMD Announces Third Quarter 2025 Financial ResultsNovember 12, 2025 | businesswire.comTherapeuticsMD Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comTherapeuticsMD: Q2 Earnings SnapshotAugust 12, 2025 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2025 Financial ResultsAugust 12, 2025 | businesswire.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29, 2025 | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe SpaceX Sell-Off May Be More Than a Market OverreactionBy Jeffrey Neal Johnson | June 24, 2026AirJoule Technologies: A Cool Shot at a MultibaggerBy Thomas Hughes | June 9, 2026SpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026How Does D-Wave's New Simulator Change the Quantum Computing Landscape?By Nathan Reiff | June 23, 2026Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?By Leo Miller | June 19, 2026OMER, TXMD, and RTRX Company DescriptionsOmeros NASDAQ:OMER$9.28 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$9.18 -0.10 (-1.13%) As of 07/2/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Travere Therapeutics NASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.TherapeuticsMD NASDAQ:TXMD$2.11 0.00 (0.00%) As of 07/2/2026 04:00 PM EasternTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
